In a double-blind phase III trial, osimertinib showed higher efficacy than standard EGFR TKIs (gefitinib or erlotinib) in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile: the median PFS was significantly longer with osimertinib than with standard EGFR TKIs (18.9 months vs. 10.2 months) [162]. Here, EGFR is linked to non-small cell lung carcinoma.